Category Archives: News

MUK nine results: Intensive treatment delivers deep responses in ultra-high risk myeloma patients

In June, the first results from the OPTIMUM/MUK nine clinical trial were presented at international conferences.
The trial is the first to use state-of-the-art diagnostics and genetic profiling to screen for patients with high-risk myeloma.
These results show that treatment with a five-drug induction treatment (Dara-CVRd) and stem cell transplant is effective and well tolerated in ultra-high risk myeloma patient

Mid-year update on myeloma treatment appraisals 

Throughout 2021, the Patient Advocacy Team have been continuing their work to support patient access to new treatments on the NHS. Read more about the four active Health Technology Appraisals including the first-ever appraisal for an AL amyloidosis treatment.

Raising HCP awareness of myeloma

Find out more about the educational resources our Clinical Practice Services Team have been developing to raise HCP awareness of myeloma.

Myeloma UK launches new funding call: Early Diagnosis for Myeloma

An update on myeloma treatments approvals and appraisals in 2021

New treatments for myeloma continue to come through the appraisal pipeline. In the last few months, there have been several new treatment approvals from both the National Institute for Healthcare Excellence (NICE) and the Scottish Medicines Consortium (SMC), which is excellent news for patients. Hopefully, there will be more good news for patients throughout 2021…

Blood Cancer Dashboard updated with new data for the devolved nations

The latest update to the Blood Cancer Dashboard, a resource developed in collaboration between Janssen and the Blood Cancer Alliance, has been launched. This includes the expansion of the resource to incorporate incidence and mortality data at a national and local level for Scotland, Wales and Northern Ireland, as well as the latest available waiting…

A new UK study recruits MGUS and smouldering myeloma patients to discover what causes myeloma.

University College London has announced the launch of a new National Cancer Research Network observational study (COSMOS) that will recruit patients with MGUS (monoclonal gammopathy of undetermined significance) and smouldering myeloma to help identify the genetic and immunological changes that cause myeloma. This ground-breaking study, which is funded by Cancer Research UK and the Medical…

Leeds CTRU launches a series of webinars to introduce the UKMRA-Myeloma UK-Concept and Access Research Programme

The Clinical Trials Research Unit (CTRU) at the University of Leeds is running a series of webinars for researchers and clinicians so they can learn all about the UKMRA-Myeloma UK-Concept and Access Research Programme (CARP) and how it supports the development of early phase myeloma trials. The webinar series will include presentations that will describe…

Myeloma UK funded research supports the need for molecular analysis at relapse

Myeloma UK funded research recently published in Leukemia shows that acquisition of new copy number aberrations is associated with relapse and therefore strongly supports the need for repeated molecular analysis at relapse. Chromosomal changes like copy number aberrations (structural amplifications, gains, or deletions) are a feature of myeloma. However, the relationship between copy number aberrations…